Tradegate
09.01.26 | 17:21
25,580 Euro
-0,70 % -0,180
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 25,340 | 25,740 | 09.01. | |
| 25,340 | 25,720 | 09.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.12.25 | Medincell: Starkes Umsatzwachstum, doch anhaltende Verluste belasten den Aktienkurs | 1 | Investing.com Deutsch | ||
| 09.12.25 | Medincell Publishes its Consolidated Half-Year Financial Results | 345 | Business Wire | (April 1st, 2025 September30, 2025)
Regulatory News:
Christophe Douat, CEO of Medincell (Paris:MEDCL)"We are pleased with the company's growth and momentum. We have entered the most transformative... ► Artikel lesen | |
| 09.12.25 | Medincell's Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults | 389 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad... ► Artikel lesen | |
| 01.12.25 | Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025 | 326 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025)
Meeting in French, 6:00... ► Artikel lesen | |
| 27.11.25 | Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference | 425 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Christophe Douat, Chief Executive Officer, Dr. Richard Malamut, Chief Medical Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will... ► Artikel lesen | |
| 24.11.25 | Medincell Awarded New Grant to Fight Malaria | 301 | Business Wire | Medincell to receive a $3 million grant from the Gates Foundation to advance mdc-STM malaria program. mdc-STM program is an investigational, three-month, subcutaneous injectable formulation of... ► Artikel lesen | |
| 13.11.25 | Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025) | 342 | Business Wire | Regulatory News:
Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overview during a fireside chat at the... ► Artikel lesen | |
| 11.11.25 | Medincell Promotes Grace Kim Chief Strategy Officer U.S. Finance | 1 | Contract Pharma | ||
| MEDINCELL Aktie jetzt für 0€ handeln | |||||
| 11.11.25 | Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth | 349 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL), a clinical-stage pharmaceutical company pioneering long-acting injectable therapies, today announced the expanded role of Dr Grace Kim, Chief Strategy... ► Artikel lesen | |
| 10.11.25 | Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark | 336 | Business Wire | Medincell has been selected for inclusion in the Morgan Stanley Capital International (MSCI) World Small Cap Index, which encompasses the most liquid and high-performing small-cap companies across... ► Artikel lesen | |
| 06.11.25 | Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York) | 390 | Business Wire | Regulatory News:
Dr Grace Kim, Chief Strategy Officer, U.S. Finance, and Dr Richard Malamut, Chief Medical Officer, will speak on Medincell's (Paris:MEDCL) value proposition, including recent... ► Artikel lesen | |
| 05.11.25 | Medincell: UZEDY Continues Strong Growth; Teva Setting the Stage for US NDA Submission for Olanzapine LAI in Q4 2025 | 473 | Business Wire | Regulatory News:
Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information:
About Olanzapine Long-Acting Injectable (TEV-749 mdc-TJK)
1-Month subcutaneous... ► Artikel lesen | |
| 22.10.25 | Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York) | 338 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will speak on Medincell's value proposition, including recent developments and meet with investors... ► Artikel lesen | |
| 13.10.25 | FDA approves Teva and Medincell's bipolar I disorder treatment | 27 | Pharmaceutical Technology | ||
| 10.10.25 | Medincell: FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder | 500 | Business Wire | FDA approves UZEDY (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar... ► Artikel lesen | |
| 23.09.25 | Teva and Medincell's Risperidone LAI Approved in Canada as LONGAVO | 574 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Teva Canada Limited, a subsidiary of Medincell's partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI... ► Artikel lesen | |
| 22.09.25 | Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed | 421 | AFX News | PETAH TIKVA (dpa-AFX) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first... ► Artikel lesen | |
| 22.09.25 | Medincell: New Data Show that UZEDY Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna | 409 | Business Wire | UZEDY was associated with a 2.89-day shorter length of hospital stay compared with Invega Sustenna (paliperidone palmitate) This translates to estimated direct cost savings of $3200 per hospitalization... ► Artikel lesen | |
| 22.09.25 | Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile - No PDSS Observed | 426 | Business Wire | There were no suspected or confirmed PDSS (Post-injection Delirium/Sedation Syndrome)1 events observed with Medincell's Olanzapine LAI through week 56 in the pivotal Phase 3 SOLARIS trial2 The... ► Artikel lesen | |
| 17.09.25 | Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation | 591 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 21, 2025,... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,60 | +0,88 % | BioNTech-Aktie: Ein guter Kauf für 2026? | Seit Anfang Dezember 2025 tritt die BioNTech-Aktie bei Kursen um die 96 US$ auf der Stelle. Auch zum Jahresstart zeigt sie wenig Bewegung. Sehen Anleger hier keine guten Investmentchancen für 2026?... ► Artikel lesen | |
| EVOTEC | 6,286 | -0,82 % | Evotec Aktie: Das große Comeback im Jahr 2026? | Nächster Anlauf der Evotec Aktie auf große charttechnische Kaufsignale - bisher misslangen diese Ausbruchsversuche. Nachdem die Biotech-Aktie in den letzten Tagen zunächst an der Unterstützung bei 5... ► Artikel lesen | |
| MEDIGENE | 0,059 | +37,56 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| MODERNA | 29,500 | +1,50 % | MODERNA: Heute ein Exot dank Impfstoff-Fortschritt. | Das Biotech-Unternehmen schafft heute eine Performance von aktuell + 9,7 %. Abgesehen vom zweiten "Exoten" AXON (+ 6,0 %), wird das Feld Top 10 klar von Halbleiter-Werten dominiert. Für den Antrieb... ► Artikel lesen | |
| VALNEVA | 4,280 | +1,61 % | Abend-Update: Abend-Update: Valneva wird beobachtet - hier braut sich etwas zusammen | ||
| AMGEN | 278,95 | -1,54 % | Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar | DJ Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar
Von Colin Kellaher
DOW JONES--Amgen hat das britische Biotechnologieunternehmen Dark Blue Therapeutics für bis zu 840 Millionen... ► Artikel lesen | |
| NOVAVAX | 6,299 | -0,08 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 318,20 | +0,95 % | VB Spine LLC: VB Spine Completes Acquisition of Cestas Manufacturing Facility from Stryker | Deal expands global manufacturing footprint and positions VB Spine for future growth in spine care VB Spine LLC ("VB Spine") today completed the acquisition of Stryker's spine implant manufacturing... ► Artikel lesen | |
| BIOGEN | 161,20 | +1,03 % | Mizuho hebt Kursziel für Biogen auf 207 Dollar an und verweist auf verbesserte Aussichten für 2026 | ||
| BIOFRONTERA | 2,430 | -3,95 % | Biofrontera erreicht wichtigen Meilenstein bei Studien zu Hauttherapien | ||
| HEIDELBERG PHARMA | 3,230 | +5,56 % | HEIDELBERG PHARMA AG zeigt fundamentale Stärke | ||
| ILLUMINA | 121,02 | -3,32 % | Illumina, Inc.: Illumina Appoints Dr. Eric Green as Chief Medical Officer | Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO SAN DIEGO, Jan. 8, 2026... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen |
Das Unternehmen MEDINCELL SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 25,580 Euro und damit -0,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDINCELL SA finden Sie auf Wallstreet Online.